Last reviewed · How we verify
Optive Advanced
At a glance
| Generic name | Optive Advanced |
|---|---|
| Sponsor | The University of New South Wales |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests (PHASE4)
- An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
- A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye (PHASE3)
- Clinical Outcomes Following Treatment With SYSTANE® BALANCE (NA)
- Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy (PHASE4)
- Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease (PHASE3)
- Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy (PHASE2)
- A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |